Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 17 and an i22 index of 20.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an... Read more
About me
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 17 and an i10 index of 22.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
About me
Doctor of Philosophy Shanghai Jiao Tong University
Doctor of Pharmacy Gomal University
Master of Philosophy University of Malakand
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 18 and an i10 index of 23.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an... Read more
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2024 |
Open access
7
7
|
2023 |
15
15
20
|
2022 |
1
|
2022 |
Open access
65
67
3
|
2022 |
86
69
12
|
Year | Output |
---|---|
2022 |
1
|
2022 |
5
|
2022 |
7
|
Year | Output |
---|---|
2024 |
Open access
7
7
|
2023 |
8
8
4
|
2023 |
15
15
20
|
2022 |
Open access
65
67
3
|
2022 |
86
69
12
|
2022 |
54
58
8
|
2022 |
Open access
56
52
4
|
2022 |
Open access
17
12
|
2022 |
14
13
1
|
2022 |
Open access
20
16
1
|
2022 |
14
14
11
|
2021 |
Open access
138
|
2021 |
78
77
|
2021 |
22
21
3
|
2021 |
Open access
16
16
2
|
2019 |
25
24
1
|
2019 |
16
15
1
|
2017 |
14
13
|
2017 |
30
28
1
|
2017 |
31
25
6
|
2016 |
73
63
3
|
Research
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 1000 citations, with an h-index of 17 and an i10 index of 22.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
External engagement & recognition
Organisation | Country |
---|---|
Abasyn University | PAKISTAN |
Affiliated Hospital of Nantong University | CHINA |
Aix-Marseille University | FRANCE |
Beijing Institute of Microbiology and Epidemiology | CHINA |
Beijing Institute of Technology | CHINA |
Capital University of Science and Technology | PAKISTAN |
China Pharmaceutical University | CHINA |
Chinese Academy of Sciences | CHINA |
Chinese PLA General Hospital | CHINA |
Guangxi Medical University | CHINA |
Guangzhou Medical University | CHINA |
Hebei University | CHINA |
Henan Normal University | CHINA |
Jiangnan University | CHINA |
Jiangsu University | CHINA |
Nankai University | CHINA |
Nantong University | CHINA |
National Center for Nanoscience and Technology of China | CHINA |
Nestlives Private Limited | INDIA |
Peking University | CHINA |
Quaid-i-Azam University | PAKISTAN |
Shandong University | CHINA |
Shanghai Jiao Tong University | CHINA |
Shanghai University | CHINA |
Shanghai Veterinary Research Institute | CHINA |
Shantou University | CHINA |
Shantou University Medical College | CHINA |
Shaqra University | SAUDI ARABIA |
Shenzhen University | CHINA |
Soochow University | CHINA |
Tianjin Medical University | CHINA |
Tianjin University | CHINA |
University of California | UNITED STATES |
University of Macau | MACAU (SAR OF CHINA) |
University of Malakand | PAKISTAN |
University of Texas Southwestern Medical Center | UNITED STATES |
Women's and Children's Hospital | AUSTRALIA |
Yangzhou University | CHINA |
Yantai University | CHINA |
Zhejiang University | CHINA |
Zhengzhou University | CHINA |